← 홈

Antibody · PD-1 / PD-L1

37개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 37개
AntibodystaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
효능 ORR 6%임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleWomen's Hospital School Of Medi…Phase 2

PD-1 inhibitor， bevacizumab (PD-1 inhibitor， bevacizumab)

Gestational Trophoblastic Neoplasia · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodyBiologicstaleGuangzhou Anjie Biomedical Tech…Phase 2

PD-1 mAb (PD-1 mAb)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodyBiologicstaleMerckPhase 3

pembrolizumab (Keytruda, PD-1 mAb, Pembrolizumab/Finotonlimab, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleZhongda HospitalPreclinical

PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab)

Hepatocellular Carcinoma · PD-1

#PD-1#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

anti-PD-1 (Pembrolizumab, Pembrolizumab (anti-PD-1))

Unresectable Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses)

HNSCC; Oral Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses)

HNSCC; Oral Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleInnoventPhase 2

PD-1 inhibitor (Sintilimab, Sintilimab (PD-1 inhibitor))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodyBiologicstaleEli LillyPhase 3

pembrolizumab (Keytruda, cetuximab+PD-1 mAb, Pembrolizumab/Finotonlimab, cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · PD-1

#PD-1#Antibody#Phase3#항체#면역항체+3
효능 ORR 0%임상시험 1상태 RECRUITING
AntibodystaleChinese PLA General HospitalPhase 2

oxaliplatin+capecitabine+bevacizumab+PD-1 antibody (oxaliplatin+capecitabine+bevacizumab+PD-1 antibody)

Colorectal Cancer; RAS Mutation · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

anti-PD-1 monoclonal antibody (pembrolizumab, pembrolizumab (anti-PD-1 monoclonal antibody))

Solid Tumor · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleShanghai Cancer Hospital, ChinaPhase 2

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE

2 / 2 페이지

← 이전다음 →